• If you are wondering whether Doximity's current share price reflects its underlying value, this article walks through what the numbers are actually saying about the stock.
• Doximity recently closed at US$26.03, with the stock showing a 6.5% return over the last 7 days and 15.7% over the last 30 days, while the year to date return stands at a 39.9% decline and the 1 year return at a 56.1% decline.
• These price moves sit against a backdrop of ongoing interest in digital tools for healthcare professionals, as investors weigh how demand for virtual collaboration and medical networking platforms might support companies in this space. At the same time, sentiment around growth stocks has been mixed, which helps explain why short term gains can appear alongside weaker year to date and 1 year returns.
• On Simply Wall St's 6 point valuation checklist, Doximity scores 5 out of 6. The next sections break down what different valuation methods say about that score, and then finish with a broader way to think about the stock's value beyond any single model.

Approach 1: Doximity Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting its future cash flows and discounting them back to today using a required rate of return. The idea is simple: the value of the stock should equal the present value of the cash it can return to shareholders over time.

For Doximity, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow stands at about $306.6 million, and analysts plus Simply Wall St projections extend out for ten years, with forecast Free Cash Flow of $419.2 million by 2031. Earlier years draw on analyst estimates, while later years are extrapolated to keep the projections consistent.

Putting these cash flows together and discounting them back, the DCF model arrives at an estimated intrinsic value of about $43.06 per share. Compared with the recent share price of $26.03, this implies the stock is trading at a 39.6% discount to that DCF estimate, which indicates that the shares may be undervalued if the cash flow assumptions are realized.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Doximity is undervalued by 39.6%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Doximity Price vs Earnings

For a profitable company, the P/E ratio is a useful way to think about value because it links what you pay today to the earnings the business is already generating. A higher or lower P/E often reflects what investors expect for future earnings growth and how much risk they see in those earnings, so there is no single “right” number, just a range that tends to look reasonable for a given profile.

Doximity currently trades on a P/E of 20.08x. That sits below the Healthcare Services industry average P/E of 27.30x and also below the peer group average of 36.04x. On the surface, this points to a lower earnings multiple than many comparable stocks in the same space.

Simply Wall St’s Fair Ratio for Doximity is 22.41x. This is a proprietary estimate of what the P/E might be given factors such as the company’s earnings growth profile, profit margins, industry, market cap and specific risks. Because it adjusts for these company level drivers rather than relying only on broad peer or industry comparisons, it offers a more tailored reference point for assessing whether the current P/E looks stretched or conservative. With the actual P/E of 20.08x below the Fair Ratio of 22.41x, the stock screens as undervalued on this measure.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Doximity Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as a simple tool on Simply Wall St’s Community page that lets you link your view of Doximity’s story to specific revenue, earnings and margin forecasts, turn those into a Fair Value, compare that Fair Value to the current price to help decide whether the stock looks attractive or expensive, and then see that view update automatically when new information like news or earnings arrives. For example, one investor might build a Narrative around a higher Fair Value such as US$56.00 based on stronger AI tools and buybacks, while another might anchor on a lower Fair Value such as US$25.00 that reflects concerns about regulation, competition and margins.

For Doximity however we will make it really easy for you with previews of two leading Doximity Narratives:

Each Narrative takes the same raw data shared earlier and pushes it in a different direction, so you can stress test your own view rather than relying on a single fair value line.

Start by asking which of these feels closer to how you see the business, then adjust the assumptions such as revenue growth, margins or the P/E you think is reasonable.

Fair Value: US$37.77

Discount or Premium vs Last Close: about 31% discount to US$26.03 based on this Narrative's fair value estimate

Revenue Growth Used: 7.04% a year

• Assumes AI workflow tools and high clinician engagement keep users active on the platform and support long run margins.
• Builds in steady revenue growth with analysts expecting US$782.1 million of revenue and US$249.4 million of earnings by 2029, and a future P/E of 33.7x.
• Sees the current price as below the US$37.77 fair value, while flagging risks such as heavy AI investment, reliance on pharma marketing and possible user saturation.

Fair Value: US$25.00

Discount or Premium vs Last Close: about 4% premium to US$26.03 based on this Narrative's fair value estimate

Revenue Growth Used: 7.13% a year

• Emphasises pressure from rising compliance costs, possible platform fatigue and tougher competition that could weigh on margins.
• Uses lower profit margin assumptions, with earnings of US$214.6 million by 2029 and a future P/E of 26.0x that sits below the US Healthcare Services industry P/E of 33.6x cited in this view.
• Treats US$25.00 as a cautious fair value anchored to the bearish analyst cohort, while still recognising strong engagement, cash generation and AI tools as potential supports.

If you want to see how these bullish and bearish setups compare side by side, including the detailed assumptions on margins, discount rates and future P/E multiples, the full Doximity Community Narratives give you that context in one place.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Doximity on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Doximity? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.